KYTX (STOCKS)
Kyverna Therapeutics, Inc. Common Stock
$8.150000
+0.095000 (+1.18%)
Prev close: $8.055000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Warner Biddle
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $495.48M
- Employees
- 129
- P/E (TTM)
- -2.48
- P/B (TTM)
- 2.49
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
4
Strong Buy
7
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.66 | $-0.77 | +0.1067 | +13.92% |
|
Dec 2025 (Q4)
|
$-0.80 | $-0.88 | +0.0755 | +8.62% |
|
Sep 2025 (Q3)
|
$-0.85 | $-0.99 | +0.1411 | +14.24% |
|
Jun 2025 (Q2)
|
$-0.97 | $-1.06 | +0.0942 | +8.85% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $7.39M |
| Operating Expenses | $163.79M |
| Research and Development | $126.36M |
| Other Operating Expenses | $37.43M |
| Operating Income/Loss | -$163.79M |
| Income/Loss From Continuing Operations After Tax | -$156.40M |
| Income/Loss From Continuing Operations Before Tax | -$156.40M |
| Net Income/Loss | -$156.40M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$156.40M |
| Net Income/Loss Available To Common Stockholders, Basic | -$156.40M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$3.27 |
| Diluted Earnings Per Share | -$3.27 |
| Basic Average Shares | 148,050,820 |
| Diluted Average Shares | 148,050,820 |
| Assets | $257.02M |
| Current Assets | $241.73M |
| Cash | $236.40M |
| Other Current Assets | $5.33M |
| Noncurrent Assets | $15.30M |
| Fixed Assets | $1.34M |
| Other Non-current Assets | $13.96M |
| Liabilities | $61.44M |
| Current Liabilities | $29.67M |
| Accounts Payable | $11.60M |
| Other Current Liabilities | $18.07M |
| Noncurrent Liabilities | $31.77M |
| Equity | $195.58M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $195.58M |
| Liabilities And Equity | $257.02M |
| Net Cash Flow From Operating Activities | -$150.39M |
| Net Cash Flow From Operating Activities, Continuing | -$150.39M |
| Net Cash Flow From Investing Activities | -$15.76M |
| Net Cash Flow From Investing Activities, Continuing | -$15.76M |
| Net Cash Flow From Financing Activities | $141.48M |
| Net Cash Flow From Financing Activities, Continuing | $141.48M |
| Net Cash Flow | -$24.68M |
| Net Cash Flow, Continuing | -$24.68M |
| Comprehensive Income/Loss | -$156.48M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$156.50M |
| Other Comprehensive Income/Loss | -$114.40M |
| Other Comprehensive Income/Loss Attributable To Parent | -$95.00K |